Cargando…

In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile

BACKGROUND: Polymethyl-methacrylate (PMMA) beads releasing antibiotics are used extensively to treat osteomyelitis, but require surgical removal afterwards because they do not degrade. METHODS: As an alternative option, this report compares the in vitro gentamicin release profile from clinically use...

Descripción completa

Detalles Bibliográficos
Autores principales: Stallmann, Hein P, Faber, Chris, Bronckers, Antonius LJJ, Nieuw Amerongen, Arie V, Wuisman, Paul IJM
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459860/
https://www.ncbi.nlm.nih.gov/pubmed/16504140
http://dx.doi.org/10.1186/1471-2474-7-18
_version_ 1782127497769385984
author Stallmann, Hein P
Faber, Chris
Bronckers, Antonius LJJ
Nieuw Amerongen, Arie V
Wuisman, Paul IJM
author_facet Stallmann, Hein P
Faber, Chris
Bronckers, Antonius LJJ
Nieuw Amerongen, Arie V
Wuisman, Paul IJM
author_sort Stallmann, Hein P
collection PubMed
description BACKGROUND: Polymethyl-methacrylate (PMMA) beads releasing antibiotics are used extensively to treat osteomyelitis, but require surgical removal afterwards because they do not degrade. METHODS: As an alternative option, this report compares the in vitro gentamicin release profile from clinically used, biodegradable carrier-materials: six injectable cements and six granule-types. Cement cylinders and coated granules containing 3% gentamicin were submerged in dH(2)O and placed in a 48-sample parallel drug-release system. At regular intervals (30, 90, 180 min. and then every 24 h, for 21 days), the release fluid was exchanged and the gentamicin concentration was measured. The activity of released gentamicin was tested on Staphylococcus aureus. RESULTS: All combinations showed initial burst-release of active gentamicin, two cements had continuous-release (17 days). The relative release of all cements (36–85%) and granules (30–62%) was higher than previously reported for injectable PMMA-cements (up to 17%) and comparable to other biodegradable carriers. From the cements residual gentamicin could be extracted, whereas the granules released all gentamicin that had adhered to the surface. CONCLUSION: The high release achieved shows great promise for clinical application of these biodegradable drug-carriers. Using the appropriate combination, the required release profile (burst or sustained) may be achieved.
format Text
id pubmed-1459860
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14598602006-05-13 In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile Stallmann, Hein P Faber, Chris Bronckers, Antonius LJJ Nieuw Amerongen, Arie V Wuisman, Paul IJM BMC Musculoskelet Disord Research Article BACKGROUND: Polymethyl-methacrylate (PMMA) beads releasing antibiotics are used extensively to treat osteomyelitis, but require surgical removal afterwards because they do not degrade. METHODS: As an alternative option, this report compares the in vitro gentamicin release profile from clinically used, biodegradable carrier-materials: six injectable cements and six granule-types. Cement cylinders and coated granules containing 3% gentamicin were submerged in dH(2)O and placed in a 48-sample parallel drug-release system. At regular intervals (30, 90, 180 min. and then every 24 h, for 21 days), the release fluid was exchanged and the gentamicin concentration was measured. The activity of released gentamicin was tested on Staphylococcus aureus. RESULTS: All combinations showed initial burst-release of active gentamicin, two cements had continuous-release (17 days). The relative release of all cements (36–85%) and granules (30–62%) was higher than previously reported for injectable PMMA-cements (up to 17%) and comparable to other biodegradable carriers. From the cements residual gentamicin could be extracted, whereas the granules released all gentamicin that had adhered to the surface. CONCLUSION: The high release achieved shows great promise for clinical application of these biodegradable drug-carriers. Using the appropriate combination, the required release profile (burst or sustained) may be achieved. BioMed Central 2006-02-26 /pmc/articles/PMC1459860/ /pubmed/16504140 http://dx.doi.org/10.1186/1471-2474-7-18 Text en Copyright © 2006 Stallmann et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Stallmann, Hein P
Faber, Chris
Bronckers, Antonius LJJ
Nieuw Amerongen, Arie V
Wuisman, Paul IJM
In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile
title In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile
title_full In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile
title_fullStr In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile
title_full_unstemmed In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile
title_short In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile
title_sort in vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459860/
https://www.ncbi.nlm.nih.gov/pubmed/16504140
http://dx.doi.org/10.1186/1471-2474-7-18
work_keys_str_mv AT stallmannheinp invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile
AT faberchris invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile
AT bronckersantoniusljj invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile
AT nieuwamerongenariev invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile
AT wuismanpaulijm invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile